Consortium partners

Biomedical Research Foundation, Academy of Athens

Mosaiques Diagnostics GmbH

Medical University Vienna

University Clinic Aachen

University of Montpellier

Institut national de la santé et de la recherche médicale

School for Cardiovascular Diseases in Maastricht (CARIM)

Karolinska Institutet

University Clinic Aachen (Aachen, Germany)

The University Clinic Aachen stands for cures, research and teaching. As a maximum-care teaching hospital, the University Clinic RWTH Aachen offers you first-class medicine with a human face. Bundling patient care, research and teaching under one roof – a concept which is unique both architecturally and in terms of organisation – facilitates intensive interdisciplinary dialogue and a dense clinical and scientific network.

Integrated within the University Clinic Aachen is the Institute for Molecular Cardiovascular Research (IMCAR), a research institute dedicated to pursuing scientific excellence in the field of cardiovascular biology with special focus on cardiovascular disease, pathological vascular remodeling processes and mass spectrometry. IMCAR is localized directly next to the Clinic for Renal and Hypertensive Disorders (Medical Clinic II), also integrated within this consortium. In addition to the organization of and active participation in clinical studies in the context of kidney failure, the institute is actively involved in research focusing on underlying pathological mechanisms of chronic renal failure.

University Clinic RWTH Aachen

Clinic for Renal and Hypertensive Disorders (Medical Clinic II)

Institute for Molecular Cardiovascular Research (IMCAR)

Project leaders:

Prof. Dr. Joachim Jankowski (IMCAR)

Dr. Heidi Noels (IMCAR)

Dr. Jürgen Floege (Medical Clinic II)

Biomedical Research Foundation, Academy of Athens (Greece, Athens)

The Biomedical Research Foundation of the Academy of Athens (BRFAA) is a non-profit institute dedicated to understanding, treating and preventing human ailments through biomedical research. BRFAA has gained prominence as one of the major Institutes for Biomedical research in Greece and researchers from the Institute have been awarded multiple competitive grants, including grants from the European Commission, such as Marie Curie fellowships, and FP6-FP7 research grants. The research team of Dr. Vlahou has vast expertise in clinical proteomics, biomarker and target discovery, protein fractionation strategies of biological samples and mass spectrometry.

www.bioacademy.gr

Project leader: Prof. Dr. Antonia Vlahou

www.bioacademy.gr/lab/vlahou

www.bioacademy.gr/faculty-details/H8M/antonia

Mosaiques Diagnostics GmbH (Hannover, Germany)

The company’s core competence is the early and reliable detection of diseases enabling personalized medicine during therapy and drug development. The company utilizes diagnostic polypeptide patterns derived from the fast and accurate analysis of proteins and polypeptides in body fluids. For this purpose, mosaiques has developed a unique technology on the basis of clinical proteome analysis, enabling the early and differential detection of cardiovascular, renal, biliary and urogenital diseases.

www.mosaiques-diagnostics.com

Project leaders:

Prof. Dr. Harald Mischak: www.researchgate.net/profile/Harald_Mischak;

Dr. Petra Zürbig: www.researchgate.net/profile/Petra_Zuerbig

Medical University Vienna (Vienna, Austria)

The Medical University of Vienna is one of the longest-standing medical training and research institutions in Europe and one of the most important cutting-edge research institutions in the field of biomedicine. It consistently strives to attract the brightest minds in order to further medical research, impart forward-thinking knowledge and ensure the best possible and most advanced care for patients.

 The Section for Clinical Biometrics belongs to the “Center for Medical Statistics, Informatics and Intelligent Systems” within the Medical University of Vienna. The section provides biostatistical as well as bioinformatical support to clinical research and develops innovative methodology for biostatistical and bioinformatical applications. This includes, among others, analysis of prognostic factors in disease studies, diagnostic studies, and analysis of observational studies. Also, the Section for Clinical Biometrics is highly expertised in the development of high-dimensional disease models taking into account correlation between biomarker candidates, with the aim to assess the value of biomarker candidates as diagnostic or predictive biomarker of disease.

www.meduniwien.ac.at/web/en/

Project leader:

Prof. Dr. Georg Heinze: https://www.researchgate.net/profile/Georg_Heinze

National Institute of Health and Medical Research (INSERM, Toulouse, France)

Founded in 1964, the French National Institute of Health and Medical Research (INSERM) is a public scientific and technological institute which operates under the joint authority of the French Ministry of Health and French Ministry of Research. INSERM’s unit 1048 (Institute of Cardiovascular and Metabolic Diseases (I2MC)) in Toulouse focuses on metabolic, cardiovascular and renal diseases. The team has significant expertise in multi biological level omics data and annotation and has, based on these analyses, identified several biomarkers of chronic renal failure with, based on current literature, a potential role in the pathology of the cardiorenal syndrome (Glorieux et al, Nephrol Dial Transplant 2015). Furthermore they have extensive expertise in the development of disease-associated omics databases. 

 

https://www.inserm.fr/en/

Project leaders:

Dr. Joost Schanstra: http://renalfibrosis.fr/team/joost-peter-schanstra/

Dr. Julie Klein: http://renalfibrosis.fr/team/julie-klein/

School for Cardiovascular Diseases in Maastricht (CARIM, Maastricht, the Netherlands)

CARIM is one of the top institutes for translational cardiovascular research in Europe. It is among the world leaders in the fields of research into vascular and thrombotic disorders and atrial fibrillation as well as translational heart failure research. It has also made important international contributions to molecular imaging in the cardiovascular field. Cardiovascular scientists from around the world have joined CARIM because it values open communication, close cooperation, high ambitions, excellent facilities and a critical learning environment.

https://www.carimmaastricht.nl/

Project leader:

Prof. Dr. Leon Schurgers: https://www.researchgate.net/profile/Leon_Schurgers

Karolinska Institutet (Karolinska, Sweden)

The Karolinska Institutet is one of the world’s foremost medical universities. Their vision is to make a significant contribution to the improvement of human health; their mission is to conduct research and education and to interact with the community. As a university, the Karolinska Institutet is Sweden’s single largest centre of medical academic research and offers the country’s widest range of medical courses and programmes. The Division of Renal Medicine within the Department of Clinical Science, Intervention and Technology is one of the largest university departments in nephrology in Scandinavia.

http://ki.se/start

Division of Renal Medicine: http://ki.se/en/clintec/division-of-renal-medicine

Project leader:

Prof. Dr. Peter Stenvinkel: https://www.researchgate.net/profile/Peter_Stenvinkel

University of Montpellier  (UM, Montpellier, France)

University of Montpellier originated from the first University established in Montpellier in 1289. The University of Montpellier gathers a multidisciplinary community of knowledge from sciences, technical arts, medicine and environmental sciences, to educational sciences, economics, law and political science. University of Montpellier coordinates the “Montpellier University of Excellence” project (MUSE), which received the Initiative – Science – Innovation– Territories – Economy (I-SITE) certification.

The Biocommunication in Cardio-Metabolism (BC2M) group of University of Montpellier, located at the Faculty of Pharmacy, is interested in the pathophysiological mechanisms involved in target organs damage in multifactorial syndromes such as the metabolic syndrome, and biocommunication between cardio-vascular, renal and metabolic tissues in this context. We conduct a multidisciplinary and integrative approach to identify new therapeutic strategies for the treatment of these complex diseases. 

https://www.umontpellier.fr/ 

Project leader:

Prof.  Anne Lajoix: https://www.umontpellier.fr/recherche/unites-de-recherche/centre-de-pharmacologie-innovation-dans-le-diabete.

© 2018 CaReSyAn

  • Facebook Social Icon
  • Twitter Social Icon

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 764474.

The content of this website reflects only the views of its authors.

The European Commission is not responsible for any use that may be made of the information it contains